Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.
The family of epidermal growth factor receptors (EGFRs) is overexpressed in many gynecologic malignancies. Extensive preclinical studies of these receptors demonstrate that they play an important role in supporting the growth of a wide variety of malignancies and that interruption of receptor function or signaling from these receptors leads to inhibition of tumor growth or in certain cases tumor regression. Recently, many therapeutic agents targeting this receptor have entered the clinic and phase II clinical studies have demonstrated activity in lung cancer, colon cancer, and head and neck malignancies. Phase II trials of both small molecule inhibitors of EGFR and antibody-based inhibitors are underway in both cervical and ovarian cancer and emerging data suggests that their activity in unselected women with advanced gynecologic malignancies is very modest. Recently, molecular analysis of lung cancers has identified that the response to small molecule inhibitors of EGFR is highly correlated with activating mutations within the EGFR. It is possible that these agents will be highly effective in a small subset of patients with gynecologic malignancies whose tumors are dependent on EGFR signaling, perhaps through an activating mutation in EGFR or its downstream pathway. Until additional research can identify the subset of patients most likely to benefit from this targeted therapy, treatment for women with gynecologic malignancies with EGFR inhibitors should be limited to investigational trials. It is critical that these trials have access to tissue of responding and nonresponding patients so to determine the rational use of these agents in the treatment of gynecologic malignancies.
Vaidya
Ami P
AP
Department of Oncology, Massachusetts General Hospital, Cox 6, 100 Blossom St., Boston, MA, 02114, USA.
Parnes
Aric D
AD
Seiden
Michael V
MV
D001682:Biological Availability; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000627:therapeutic use*; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D006801:Humans; D020714:Maximum Tolerated Dose; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology
D066246:ErbB Receptors
J Clin Oncol. 2002 May 1;20(9):2240-50
11980995
J Clin Oncol. 2004 Aug 1;22(15):3003-15
15210739
Oncology (Williston Park). 2003 Nov;17(11 Suppl 12):23-8
14682120
Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23
11255078
J Clin Oncol. 2002 Nov 1;20(21):4292-302
12409327
Cancer Res. 2001 Mar 1;61(5):2169-76
11280782
Ai Zheng. 2004 May;23(5):568-72
15142456
Br J Cancer. 2006 Jan 16;94(1):85-92
16306877
J Clin Oncol. 2001 Jul 1;19(13):3267-79
11432895
Clin Cancer Res. 1999 Mar;5(3):577-86
10100709
Ann Oncol. 2003 Jun;14(6):922-30
12796031
Cancer Res. 1995 Dec 1;55(23):5536-9
7585629
J Clin Oncol. 2003 Jan 15;21(2):283-90
12525520
Science. 2004 Jun 4;304(5676):1497-500
15118125
Tumour Biol. 1998;19(5):364-73
9701727
Clin Pharmacokinet. 2001;40(4):297-306
11368294
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
Int J Gynecol Cancer. 2001 Mar-Apr;11(2):119-29
11328410
J Natl Cancer Inst. 2001 Sep 19;93(18):1375-84
11562388
Br J Cancer. 1995 Apr;71(4):758-62
7710941
J Clin Oncol. 2004 Jan 1;22(1):175-84
14701780
Gynecol Oncol. 1999 Apr;73(1):62-71
10094882
Int J Biochem Cell Biol. 1999 Jun;31(6):637-43
10404636
Cancer Treat Rev. 2004 May;30(3):255-68
15059649
Cancer. 2001 Dec 15;92(12):3068-75
11753986
Br J Cancer. 2004 Feb 9;90(3):566-72
14760365
J Biol Chem. 1999 Jun 18;274(25):17612-8
10364198
J Clin Oncol. 2002 Sep 15;20(18):3815-25
12228201
Clin Cancer Res. 1999 Oct;5(10):2877-83
10537356
J Pharmacol Exp Ther. 1999 Nov;291(2):739-48
10525095